Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database.

JCO Precis Oncol · 2026 · PMC12799258 · PMID 41505680

Europe PMC DOI

hedged sentence

0.0930

closest p · 1.9× alpha

0.0930

boldest claim

The sentences

did not reach statistical significanceP = .093so close (0.05 < p ≤ 0.1)

Similarly, the DCR was also lower in patients with RAS amplification (66.1% [37/56] v 75.9% [1,209/1,593]), but this difference did not reach statistical significance ( P = .093).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.